MBX Biosciences, Inc. (Nasdaq: MBX), a biopharmaceutical company in the clinical stage, has announced its participation in multiple investor conferences scheduled for November 2025. The company specializes in developing innovative precision peptide therapies aimed at treating endocrine and metabolic disorders.
On November 10, 2025, Kent Hawryluk, President and Chief Executive Officer, along with Sam Azoulay, M.D., Chief Medical Officer, will engage with investors during the Guggenheim 2nd Annual Healthcare Innovation Conference. The session will include a fireside chat and individual meetings, taking place from 3:30 PM to 3:55 PM ET in Boston, MA.
Following this, they will participate in the Stifel Healthcare Conference on November 12, 2025, from 3:20 PM to 3:50 PM ET in New York, NY, where they will also conduct a fireside chat and one-on-one meetings.
On November 19, 2025, they will present at the Jefferies Global Healthcare Conference in London, UK, with a scheduled time of 4:00 PM to 4:25 PM GMT. This conference will similarly feature a fireside chat format and opportunities for direct engagement with investors.
Lastly, on November 24, 2025, they will be part of the virtual TD Cowen Treatment Advancements in Obesity and Related Disorders Summit, where they will again participate in a fireside chat and one-on-one meetings from 10:00 AM to 10:25 AM ET.
The live webcasts of these events will be accessible through the events section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Replays will be available approximately two hours after each event ends and will remain archived on the company”s website for around 90 days.
About MBX Biosciences
Based in Carmel, Indiana, MBX Biosciences is dedicated to discovering and developing novel precision peptide therapies utilizing its proprietary PEPTM platform. The company is advancing a robust pipeline targeting endocrine and metabolic disorders, with candidates that address significant unmet medical needs and have established potential for regulatory approval and market impact.
Among the promising treatments in development are canvuparatide (MBX 2109), aimed at chronic hypoparathyroidism and preparing for Phase 3 trials, and imapextide (1416), which is in Phase 2 trials for post-bariatric hypoglycemia. The company also has an obesity portfolio, including MBX 4291 in Phase 1 development, alongside various candidates in discovery and pre-clinical phases.
For further information, please visit the company”s website at https://mbxbio.com/ and connect with them on LinkedIn.
Media Contact:
Katie Beach Oltsik
Inizio Evoke Comms
[email protected]
(937) 232-4889
Investor Contact:
Jim DeNike
MBX Biosciences
[email protected]
